Lung ultrasound-guided therapy reduces acute decompensation events in chronic heart failure. Issue 24 (22nd June 2020)

• Record Type: Journal Article
• Authors: Marini, Claudia; Fragasso, Gabriele; Italia, Leonardo; Sisakian, Hamayak; Tufaro, Vincenzo; Ingallina, Giacomo; Stella, Stefano; Ancona, Francesco; Loiacono, Ferdinando; Innelli, Pasquale; Costantino, Marco Fabio; Sahakyan, Laura; Gabrielyan, Sirvard; Avetisyan, Mariam; Margonato, Alberto; Agricola, Eustachio
• Is Part Of: Heart. Volume 106:Issue 24(2020)
• Page Start: 1934
• Page End: 1939
• Publication Date: 2020-06-22
• Subjects: heart failure -- heart failure with reduced ejection fraction; Heart -- Diseases -- Treatment -- Periodicals; Cardiology -- Periodicals; 616.12
• DOI: 10.1136/heartjnl-2019-316429
• Languages: English
• ISSNs: 1355-6037

Abstract

Abstract : Objective: Pulmonary congestion is the main cause of hospital admission in patients with heart failure (HF). Lung ultrasound (LUS) is a useful tool to identify subclinical pulmonary congestion. We evaluated the usefulness of LUS in addition to physical examination (PE) in the management of outpatients with HF. Methods: In this randomised multicentre unblinded study, patients with chronic HF and optimised medical therapy were randomised in two groups: 'PE+LUS' group undergoing PE and LUS and 'PE only' group. Diuretic therapy was modified according to LUS findings and PE, respectively. The primary endpoint was the reduction in hospitalisation rate for acute decompensated heart failure (ADHF) at 90-day follow-up. Secondary endpoints were reduction in NT-proBNP, quality-of-life test (QLT) and cardiac mortality at 90-day follow-up. Results: A total of 244 patients with chronic HF and optimised medical therapy were enrolled and randomised in 'PE+LUS' group undergoing PE and LUS, and in 'PE only' group. Thirty-seven primary outcome events occurred. The hospitalisation for ADHF at 90 day was significantly reduced in 'PE+LUS' group (9.4% vs 21.4% in 'PE only' group; relative risk=0.44; 95% CI 0.23 to 0.84; p=0.01), with a reduction of risk for hospitalisation for ADHF by 56% (p=0.01) and a number needed to treat of 8.4 patients (95% CI 4.8 to 34.3). At day 90, NT-proBNP and QLT score were significantly reduced in 'PE+LUS' group, whereas in 'PE only' group both were increased. There were no differences in mortality between the two groups. Conclusions: LUS-guided management reduces hospitalisation for ADHF at mid-term follow-up in outpatients with chronic HF.